...
首页> 外文期刊>OncoTargets and therapy >FAM110B Inhibits Non-Small Cell Lung Cancer Cell Proliferation and Invasion Through Inactivating Wnt/β-Catenin Signaling
【24h】

FAM110B Inhibits Non-Small Cell Lung Cancer Cell Proliferation and Invasion Through Inactivating Wnt/β-Catenin Signaling

机译:FAM110B通过灭活WNT /β-Catenin信号传导抑制非小细胞肺癌细胞增殖和侵袭

获取原文
           

摘要

Purpose: FAM110B is a member of the FAM110 family (family with sequence similarity 110), which is a component of the centrosome associated proteins. Previous studies have shown that FAM110B may be involved in the process of cell cycle and may play a role in carcinogenesis and tumor progression. Using an online database, we found that FAM110B may predict favorable prognosis in non-small cell lung cancer (NSCLC). Therefore, the role of FAM110B playing in NSCLC needs to be further investigated. Patients and Methods: Online databases and immunohistochemistry were used to predict the expression and prognostic value of FAM110B in NSCLC samples. Immunofluorescence staining was used to investigate the subcellular distribution of FAM110B. Western blot, MTT, colony formation, and matrigel invasion assay were used to detect the expression and the effect of FAM110B on mediating proliferation and invasion in NSCLC cell lines. Results: In this study, immunohistochemistry results showed that FAM110B expression significantly correlated with early TNM staging ( P =0.020) and negative regional lymph node metastasis ( P =0.006). Kaplan–Meier survival analysis found that the median survival time of patients with positive FAM110B expression (56.181± 2.348 months) was significantly longer than those with negative FAM110B expression (47.701± 2.997 months, P =0.024). Moreover, overexpression of FAM110B inhibited the proliferation and invasion of A549, H1299, and LK2 cell lines. Conversely, FAM110B RNAi exerted opposite effects in the above cell lines. Furthermore, FAM110B overexpression downregulated the active β‐catenin, phosphorylation of GSK-3β (p-GSK-3β), cyclin B1, cyclin D1, MMP2, and MMP7, and upregulated the phosphorylation of β-catenin (p-β-catenin) in A549 and H1299 cells. Besides, the FAM110B-induced depressions of p-GSK-3β and active β-catenin were reversed after being treated with Wnt/β-catenin inhibitor, XAV-939. Conclusion: In summary, our results demonstrated that the overexpression of FAM110B restricts the proliferation and invasion of NSCLC cells by inhibiting Wnt/β-catenin signaling. Our study reveals the antitumor function of FAM110B in NSCLC and indicates that FAM110B is a potential therapeutic target.
机译:目的:FAM110B是FAM110系列的成员(具有序列相似度110的家庭),这是Centosome相关蛋白的一个组成部分。以前的研究表明,FAM110B可以参与细胞周期的过程,并且可能在致癌物中发挥作用和肿瘤进展。使用在线数据库,我们发现FAM110B可以预测非小细胞肺癌(NSCLC)的良好预后。因此,FAM110B在NSCLC中使用FAM110B的作用需要进一步调查。患者和方法:在线数据库和免疫组织化学用于预测FAM110B在NSCLC样品中的表达和预后值。使用免疫荧光染色来研究FAM110B的亚细胞分布。用于检测FAM110B对NSCLC细胞系中介导的增殖和侵袭的表达和Matrigel侵袭测定和Matrigel侵袭测定。结果:在该研究中,免疫组织化学结果表明,FAM110B表达与早期TNM分期显着相关(P = 0.020)和阴性区域淋巴结转移(P = 0.006)。 Kaplan-Meier生存分析发现,阳性FAM110B表达患者的中位存活时间(56.181±2.348个月)明显长于阴性FAM110B表达(47.701±2.997个月,P = 0.024)。此外,FAM110B的过表达抑制A549,H1299和LK2细胞系的增殖和侵袭。相反,FAM110B RNAi在上述细胞系中施加相反的效果。此外,FAM110B过表达下调了活性β-Catenin,GSK-3β(P-GSK-3β),细胞周期蛋白B1,Cyclin D1,MMP2和MMP7的磷酸化,并上调了β-catenin的磷酸化(p-β-catenin)在A549和H1299细胞中。此外,在用Wnt /β-catenin抑制剂XAV-939处理后,FAM110B诱导的P-GSK-3β和活性β-Catenin的凹陷逆转。结论:总之,我们的结果表明,FAM110B的过表达通过抑制WNT /β-Catenin信号传导来限制NSCLC细胞的增殖和侵袭。我们的研究揭示了NSCLC中FAM110B的抗肿瘤功能,并表明FAM110B是潜在的治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号